Is Idexx Laboratories (IDXX) overvalued or fairly valued?

MarketChacha shows Idexx Laboratories's valuation in context — a trailing P/E of about 37.7, a forward P/E of about 33.2, a price-to-book of about 27.2 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

Does Idexx Laboratories's reported profit turn into cash?

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash. MarketChacha computes this cash-conversion check (1.08×) from reported figures — education, not a rating.

What is Idexx Laboratories's revenue?

Idexx Laboratories reported revenue of $4.3B for FY2025, with net profit of $1.1B, per official filings.

What is the share price of Idexx Laboratories (IDXX)?

Idexx Laboratories last traded at $556.46 (+0.1% on the day), as of 10/20/2026 — a delayed quote shown for education, not investment advice.

Idexx Laboratories

IDXX · NASDAQ · Healthcare · United States

Snapshot

TickerIDXX

ExchangeNASDAQ

SectorHealthcare

IndustryDiagnostics & Research

CountryUnited States

Employees11,000

HeadquartersWestbrook, United States

Websitewww.idexx.com

Filings tracked16

About Idexx Laboratories

IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally. It operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy. The company offers point-of-care diagnostic solutions, blood and urine chemistry, hematology, immunoassay, urinalysis, cytology/morphology, and coagulation analyzers; and SNAP rapid assays test kits. It also provides commercial reference laboratory diagnostic and consulting services to veterinarians; veterinary consultation, telemedicine, and advisory services, including radiology, dental radiography, cardiology, internal medicine, and ultrasound consulting; Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, Quanti-Tray products, and Tecta system instruments; UV Viewer Plus, a UV light cabinet which aids in the visual interpretation of fluorescent-based water tests; and veterinary software and services for independent veterinary clinics and corporate groups. In addition, the company offers diagnostic tests, services, and related instrumentation to manage the health status of livestock and poultry; human medical diagnostic products and services; and VetConnect PLUS, a cloud-based technology that enables veterinarians to access and analyze patients, as well as operates VetLab Station. It markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.

Who owns it

Insiders0.2%
Institutions96.8%
Public & other3.0%

1,850 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.10.37%
Vanguard Capital Management LLC6.54%
Vanguard Portfolio Management LLC4.95%
State Street Corporation4.76%
Invesco Ltd.4.58%
Geode Capital Management, LLC3.25%
BAMCO Inc.2.51%
Morgan Stanley1.72%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

No major accounting red flags in the fundamentals we have — profit is backed by cash and returns look healthy.

Cash conversion1.08×

Over 3 years, operating cash flow fully covered reported profit — earnings are backed by real cash.

Net margin trend23.1% → 24.6%

Margin has expanded by about 1.5 points — the business is getting more profitable.

Return on equity66.0%

Latest ROE of 66.0% — capital is generating a healthy return.

Growth qualityrev 8% · PAT 12%

Profit growth is broadly tracking revenue growth — the earnings trend looks operational rather than one-off.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $1.2B · EPS 3.36

Est. earnings growth +9.1%

Next fiscal year

Rev $5.1B · EPS 16.74

Est. earnings growth +12.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$4.3B

Net margin

24.6%

ROE

66.0%

Revenue CAGR (2y)

+8.4%

Profit CAGR (2y)

+12.0%

EPS (FY2025)

13.08

Net profit (FY2025)

$1.1B

Ask MarketChacha about IDXX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$4.3B	$1.1B	13.08	24.6%	66.0%
FY2024	$3.9B	$887.9M	10.67	22.8%	55.7%
FY2023	$3.7B	$845.0M	10.06	23.1%	56.9%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$1.2B	$338.4M	4.27	27.8%
2026Q1	$1.1B	$278.4M	3.47	24.4%
2025Q3	$1.1B	$274.6M	3.40	24.8%
2025Q2	$1.1B	$294.0M	3.63	26.5%
2025Q1	$998.4M	$242.7M	2.96	24.3%
2024Q3	$975.5M	$232.8M	2.80	23.9%
2024Q2	$1.0B	$203.3M	2.44	20.3%
2024Q1	$964.1M	$235.6M	2.81	24.4%
2023Q3	$915.5M	$212.2M	2.53	23.2%
2023Q2	$943.6M	$224.2M	2.67	23.8%
2023Q1	$900.2M	$214.1M	2.55	23.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

10-Q filing
SEC8/4/2026
8-K — Results of operations, Exhibits
SEC8/4/2026material
8-K — Bylaw/charter change, Shareholder vote results, Exhibits
SEC5/15/2026material
8-K — Results of operations, Exhibits
SEC5/5/2026material
10-Q filing
SEC5/5/2026
8-K — Executive/director change, Exhibits
SEC3/26/2026material
10-K filing
SEC2/20/2026
8-K — Executive/director change
SEC2/13/2026material
8-K — Results of operations, Exhibits
SEC2/2/2026material
8-K — Executive/director change, Reg FD disclosure, Exhibits
SEC1/13/2026material

2025

8-K — Material agreement, Material financial obligation, Exhibits
SEC11/13/2025material
8-K — Results of operations, Exhibits
SEC11/3/2025material
10-Q filing
SEC11/3/2025
8-K — Executive/director change, Exhibits
SEC10/7/2025material
8-K — Results of operations, Exhibits
SEC8/4/2025material
10-Q filing
SEC8/4/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.